ArticleNature2023
Pharmacological targeting of netrin-1 inhibits EMT in cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
18.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 122 citations in OpenAlex.
- NCEH1 promotes breast cancer progression by regulating NRP1 and activating the TNF-α/NF-κB signalling pathway.Cell adhesion & migration · 2026Article
- TGF‑β1 in cancer: From tumour suppressor to promoter, molecular mechanisms, and precision therapeutic strategies (Review).International journal of oncology · 2026Review
- UNC5B regulates epithelial-to-mesenchymal transition through a SRC-ZEB1 signaling axis to facilitate pancreatic cancer metastasis.Oncogene · 2026Article
- FTO-Driven m6A Demethylation of TNC Promotes Epithelial-Mesenchymal Transition and Gastric Cancer Metastasis.Biomedicines · 2026Article
- Epithelial-mesenchymal transition in carcinoma: navigating phenotypic states to target resistance and metastasis.Cancer metastasis reviews · 2026Review
- Metabolic-epigenetic reprogrammingActa pharmaceutica Sinica. B · 2026Article
- Single cell multiomics unravel the transcription networks controlling the different EMT tumor states.Nature communications · 2026Article
- The SHH/GLI target Netrin-1 supports self-renewal in medulloblastoma tumor cells.Cell communication and signaling : CCS · 2026Article
- Article
- A ZEB1-Neon knock-in uncovers traceable dynamics of epithelial-mesenchymal transition in tumors in vivo.BMC biology · 2026Article
- Deciphering functional intra-tumoral heterogeneity in BRAFOncogene · 2026Article
- UNC5B activates hepatic stellate cells and promotes liver fibrosis via FAK.Cell communication and signaling : CCS · 2026Article
- ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer.Nature communications · 2026Article
- Netrin-1 Promotes Pancreatic Tumorigenesis and Innervation through NEO1.Cancer research · 2026Article
- Advances in the treatment of cutaneous tumors: from conventional therapies to targeted and immunotherapeutic strategies.World journal of surgical oncology · 2026Review
- Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity.Nature cancer · 2026Review
- Frazzled/DCC directs spatial progenitor integration ensuring steady-state intestinal turnover.Nature communications · 2026Article
- The Neuro-Bone Axis in Metastatic Progression: Innervation, Neuro-Immune-Osteoclast Crosstalk, and Therapeutic Opportunities.Biology · 2026Review
- Netrin-1 disrupt high-fat-diet-induced adipogenesis via the PPARγ and Wnt/β-catenin signaling pathways.Communications biology · 2026Article
- Autocrine Netrin-1 Signaling in Hepatic Stellate Cells Drives Liver Fibrosis and Diet-Induced Metabolic Dysfunction-Associated Steatohepatitis in Mice.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors at 4 institutions in 2 countries.
Justine Lengrand *Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Ievgenia Pastushenko *Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Sebastiaan Vanuytven *Department of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium.ORCID 0000-0001-6723-0132
Yura SongLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
David VenetLaboratory of Breast Cancer Translational Research J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Rahul M SarateLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Melanie BellinaNETRIS Pharma, Lyon, France.
Virginie MoersLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Alice BoinetLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Alejandro SifrimLaboratory of Multi-omic Integrative Bioinformatics, Center for Human Genetics, KU Leuven, Leuven, Belgium.
Nicolas RamaLaboratory Apoptosis, Cancer and Development, Equipe labellisee 'La Ligue', LabEx DEVweCAN, Institute PLAsCAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052-CNRS UMR5286, Lyon, France.ORCID 0000-0003-1614-7755
Benjamin DucarougeNETRIS Pharma, Lyon, France.ORCID 0000-0002-6701-0508
Jens Van HerckDepartment of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium.ORCID 0000-0002-1291-4462
Christine DuboisLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Samuel ScozzaroLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Sophie LemaireLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Sarah GieskesLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Sophie BonniLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Amandine CollinDIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Jumet, Belgium.
Nicolas BraissandNETRIS Pharma, Lyon, France.
Justine AllardDIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Jumet, Belgium.
Egor ZindyDIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Jumet, Belgium.ORCID 0000-0003-0033-0002
Christine DecaesteckerDIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Jumet, Belgium.
Christos SotiriouLaboratory of Breast Cancer Translational Research J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Brussels, Belgium.
Isabelle SalmonDIAPath, Center for Microscopy and Molecular Imaging, Université Libre de Bruxelles (ULB), Jumet, Belgium.
Patrick MehlenNETRIS Pharma, Lyon, France. patrick.mehlen@lyon.unicancer.fr.ORCID 0000-0003-1743-5417
Thierry VoetDepartment of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium.ORCID 0000-0003-1204-9963
Agnès BernetNETRIS Pharma, Lyon, France. agnes.bernet@lyon.unicancer.fr.ORCID 0000-0002-8260-9711
Cédric BlanpainLaboratory of Stem Cells and Cancer, Université Libre de Bruxelles (ULB), Brussels, Belgium. cedric.blanpain@ulb.be.ORCID 0000-0002-4028-4322
Université Libre de Bruxelles · BEUniversité Claude Bernard Lyon 1 · FRKU Leuven · BENetris Pharma (France) · FR
Funding
European Research Council 885093
Abstract
Epithelial-to-mesenchymal transition (EMT) regulates tumour initiation, progression, metastasis and resistance to anti-cancer therapy
Indexed as
Antibodies, MonoclonalCarcinoma, Squamous CellEpithelial-Mesenchymal TransitionNetrin-1Skin NeoplasmsA549 CellsAnimalsAntibodies, Monoclonal, HumanizedCell Line, TumorDisease Models, AnimalEpithelial Cell Adhesion MoleculeHumansMiceNeoplasm MetastasisNetrin ReceptorsRNA-SeqAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedEpithelial Cell Adhesion MoleculeNetrin-1netrin-1 inhibitor NP137Netrin ReceptorsNTN1 protein, humanNtn1 protein, mouseRNA, Small InterferingTGFB1 protein, humanTransforming Growth Factor beta1Unc5b protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.